Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

NCT01436227 PHASE2 COMPLETED Results posted

This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with von Hippel-Lindau syndrome. Pazopanib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Details

Lead sponsor	M.D. Anderson Cancer Center
Phase	PHASE2
Status	COMPLETED
Enrolment	32
Start date	Tue Jan 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Mar 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Von Hippel-Lindau Syndrome

Interventions

• Laboratory Biomarker Analysis
• Pazopanib Hydrochloride

Countries

United States